Cystectomy clinical trials

Explore recruiting cystectomy clinical trials.

Recruiting cystectomy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cystectomy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Germany, Netherlands, Spain, Belgium, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Treatment Of Metastatic Bladder cancer at the time Of biochemical reLApse following radical cystectomy - TOMBOLA

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

Greece, France, Spain, Portugal, Poland, Italy +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

IMPACT – the introduction of mycotic prophylaxis at cystectomy trial. Perioperative mycotic prophylaxis to reduce postoperative complications following cystectomy – a double-blinded, placebo-controlled, randomized trial.

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

REINFORCE – Reducing infection-related readmissions following cystectomy. A multicentre randomised clinical trial testing superiority of individualised targeted antibiotic prophylaxis over empiric prophylaxis at ureteral stent removal to reduce infection-related readmissions following cystectomy.

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)

Italy, Denmark, Poland, Ireland, Sweden, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cystectomy trials by city

Cystectomy in Toronto Cystectomy in Vancouver Cystectomy in Montreal Cystectomy in Calgary Cystectomy in Edmonton Cystectomy in Ottawa Cystectomy in Winnipeg Cystectomy in Quebec City Cystectomy in Hamilton Cystectomy in Kitchener Cystectomy in London Cystectomy in Halifax Cystectomy in New York Cystectomy in Los Angeles Cystectomy in Chicago Cystectomy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease